Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 99 |
| Updated: | 1/12/2019 |
| Start Date: | August 9, 2016 |
| End Date: | July 18, 2019 |
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors
This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK,
immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid
tumors.
immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid
tumors.
Inclusion Criteria:
- Male and female subjects
- 18 years and older
- Must have histologic documentation of advanced solid tumors
- Must have received and have progressed, are refractory or, intolerant to standard
therapy and must not have a curative therapy option
Exclusion Criteria:
- Concurrent enrollment in another clinical study
- Prior participation in clinical studies that include durvalumab alone or in
combination
- Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer
treatment
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials